Free US stock valuation multiples and PEG ratio analysis to identify reasonably priced growth companies. Our valuation framework helps you find stocks with the right balance of growth and value characteristics.
BioCryst shares have experienced notable weakness in recent trading sessions, with the stock declining 4% in the latest period to trade near $9.19. The move comes amid a broader pullback across small-cap biotechnology names, as sector sentiment remains sensitive to both clinical-stage pipeline updat
BioCryst (BCRX) Slides -4.02% as Selling Pressure Mounts 2026-05-15 - IPO Watch
BCRX - Stock Analysis
4935 Comments
1946 Likes
1
Hazen
Trusted Reader
2 hours ago
I read this and forgot what I was doing.
👍 55
Reply
2
Keyoni
Community Member
5 hours ago
Who else is thinking the same thing right now?
👍 283
Reply
3
Tandice
Returning User
1 day ago
As someone who checks regularly, I’m surprised I missed it.
👍 159
Reply
4
Draysen
Daily Reader
1 day ago
Investor sentiment is cautiously optimistic, as indices hold above key support levels. Minor intraday pullbacks have not disrupted the broader trend. Market participants are advised to track sector rotations to anticipate potential breakout opportunities.
👍 140
Reply
5
Keston
Community Member
2 days ago
I don’t understand but I’m aware.
👍 248
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.